LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Elanco Animal Health Inc

Closed

SectorHealthcare

18.79 -1.21

Overview

Share price change

24h

Current

Min

18.56

Max

19

Key metrics

By Trading Economics

Income

-56M

11M

Sales

48M

1.2B

P/E

Sector Avg

21.648

35.733

Profit margin

0.886

Employees

9,000

EBITDA

3M

264M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-5.51% downside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

2.5B

9.5B

Previous open

20

Previous close

18.79

News Sentiment

By Acuity

50%

50%

156 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Elanco Animal Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 May 2025, 11:29 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Million

5 May 2025, 11:14 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 May 2025, 10:50 UTC

Acquisitions, Mergers, Takeovers

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 May 2025, 10:49 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

Peer Comparison

Price change

Elanco Animal Health Inc Forecast

Price Target

By TipRanks

-5.51% downside

12 Months Forecast

Average 18 USD  -5.51%

High 21 USD

Low 15 USD

Based on 9 Wall Street analysts offering 12 month price targets forElanco Animal Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

9.77 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

156 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
help-icon Live chat